Journals / Göztepe Tıp Dergisi / 2010 / Cilt: 25 - Sayı: 2

Evaluation of the efficacy of intravitreal injection of triamsinolone acetonide in patients with diabetic macular edema

Diyabetik maküla ödemi olan olgularda intravitreal triamsinolon asetonid enjeksiyonu etkinliğinin değerlendirilmesi

Pages
71–77
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thevisual acuity improved significiantly from baseline at the firstweek, first months, 3. months and 6. months (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To investigate the visual acuity, intraocular pressureand central macular thickness response after intravitreal triamcinolone acetonide injection (IVTA 0.1 ml/4 mg) for treatingdiabetic macular edema (DME).
📊
Key Findings & Data:Material and methods: Fifty eyes of 50 patients with DMEwere included in the study.
💡
Conclusion & Impact:Thevisual acuity improved significiantly from baseline at the firstweek, first months, 3. months and 6. months (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To investigate the visual acuity, intraocular pressureand central macular thickness response after intravitreal triamcinolone acetonide injection (IVTA 0.1 ml/4 mg) for treatingdiabetic macular edema (DME). Material and methods: Fifty eyes of 50 patients with DMEwere included in the study. Triamcinolone acetonide (TA) 0.1ml/4mg was injected intravitreally under topical anesthesia.The best corrected visual acuity (BCVA), intraocular pressure(IOP) and central macular thickness (CMT) with optic cohorence tomography (OCT) values before and 1 week, 1 month, 3months and 6 months after IVTA injection were noted. Results: The mean age of patients were 59.60±11.62 (35-80year), the mean follow-up period was 7.36±4.51 months (6-24months). The visual acuity of the patients were 0.19±0.16 before injection and after injection 1. week 0.20±0.16, 1. month0.26±0.20, 3. months 0.28±0.20 and 6. months 0.23±0.21. Thevisual acuity improved significiantly from baseline at the firstweek, first months, 3. months and 6. months (p

Özet

Amaç: Diyabetik maküla ödemi (DMÖ) olan olgularda intravitreal 0.1 ml/4 mg triamsinolon asetonid enjeksiyonu (IVTA)sonrasında görme keskinliği (GK), göziçi basıncı (GİB) vesantral maküla kalınlığı (SMK) değişimlerini incelemek. Gereç ve Yöntem: Diffüz diyabetik maküla ödemi olan 50hastanın 50 gözü çalışmaya alındı. Topikal anestezi altında0.1 ml/4 mg triamsinolon asetonid (TA) intravitreal olarakenjekte edildi. Hastalarda düzeltilmiş en iyi görme keskinliği(DEİGK), göziçi basınçları (GİB) ve optik kohorens tomog- rafi (OKT) ile SMK değerleri belirlendi. Hastaların enjeksiyon sonrası 1. gün, 1. hafta, 1. ay, 3. ay, ve 6. ayda kontrolleri yapıldı.Bulgular: Hastaların ortalama yaşı 59.60±11.62 (35-80 yıl),ortalama takip süresi 7.36±4.51 ay (6-24 ay) idi. Hastalarınenjeksiyon öncesi görme keskinliği 0.19±0.16 olup enjeksiyonutakiben görme keskinliği 1.hafta 0.20±0.16, 1.ay 0.26±0.20, 3.ay 0.28±0.20 ve 6. ay 0.23±0.21 idi. Preoperatif görme keskinliğine göre 1. hafta, 1. ay, 3. ay ve 6. ay görme keskinliğindeartış istatistiksel olarak anlamlı bulundu (p

🔖

Cite This Article

ACAR, T. B., ACAR, S. (2022). Evaluation of the efficacy of intravitreal injection of triamsinolone acetonide in patients with diabetic macular edema. Göztepe Tıp Dergisi, Cilt: 25 - Sayı: 2, 71–77. https://ajindex.com/articles/526165

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Yıldırım Y, Ayata A, Ünal M, Sönmez M, Karadayı K, Gülecek O. Klasik Tedaviye Dirençli Diffüz Diabetik Maküla Ödeminde İntravitreal Triamsinolon Asetonid Etkinliği. RetVit 2005;13:261-266
  2. Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insul independent diabetes mel l i tus. N Engl J Med 1993;329:977-986
  3. UK Prospective Diabetes Study Group: Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33 1998; Lancet 352:837-853
  4. The Eye: Fundamentals and Principles of Ophthalmology. American Academy of Ophthalmology. LEO 2000: section II:68-88
  5. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985;103:1796-806
  6. Moss SE, Klein R, Klein BEK. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003
  7. Bresnick GH. Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-17
  8. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema: long-term visual results. Ophthalmology 1991;98:1594-1602
  9. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000;130:178-86
  10. Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 1979;77:171-180
  11. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-427
  12. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one year results. Arch Ophthalmol 2003;121:667-673
  13. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-195
  14. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41:3569-3575
  15. Jonas JB, Hayler JK, Sofker A, e